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Abstract
The conversion of androgen receptor (AR) signaling as a mechanism of growth suppression of normal prostate epithelial
cells to that of growth stimulation in prostate cancer cells is often associated with AR mutation, amplification and over-
expression. Thus, down-regulation of AR signaling is commonly therapeutic for prostate cancer. The E006AA cell line was
established from a hormone naı ¨ve, localized prostate cancer. E006AA cells are genetically aneuploid and grow equally well
when xenografted into either intact or castrated male NOG but not nude mice. These cells exhibit: 1) X chromosome
duplication and AR gene amplification, although paradoxically not coupled with increased AR expression, and 2) somatic,
dominant-negative Serine-599-Glycine loss-of-function mutation within the dimerization surface of the DNA binding
domain of the AR gene. No effect on the growth of E006AA cells is observed using targeted knockdown of endogenous
mutant AR, ectopic expression of wild-type AR, or treatment with androgens or anti-androgens. E006AA cells represent a
prototype for a newly identified subtype of prostate cancer cells that exhibit a dominant-negative AR loss-of-function in a
hormonally naı ¨ve patient. Such loss-of-function eliminates AR-mediated growth suppression normally induced by normal
physiological levels of androgens, thus producing a selective growth advantage for these malignant cells in hormonally
naı ¨ve patients. These data highlight that loss of AR-mediated growth suppression is an independent process, and that,
without additional changes, is insufficient for acquiring oncogene addiction to AR signaling. Thus, patients with prostate
cancer cells harboring such AR loss-of-function mutations will not benefit from aggressive hormone or anti-AR therapies
even though they express AR protein.
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Introduction
Within the last decade there has been a renewed interest in
androgen receptor (AR) signaling, as it pertains to normal prostatic
function, prostate carcinogenesis, and metastatic progression. In
the normal prostate, AR functions via a reciprocal paracrine
interaction between the epithelial and stromal cells [1]. Androgen
binding to the AR in prostate stromal cells activates a
transcriptional cascade resulting in the production and secretion
of paracrine growth factors, known as andromedins, which diffuse
into the epithelial compartment, bind cell surface cognate
receptors, and activate signaling pathways that stimulate the
proliferation and survival of the epithelial cells [1]. In the presence
of physiological levels of androgen, and thus andromedins, ligand-
bound AR located in the secretory luminal epithelial cell prevents
the overgrowth of the epithelial compartment by suppressing cell
proliferation and promoting cellular differentiation [1,2,3,4]. The
importance of this cell context-dependent AR growth-suppressive
ability is documented by studies showing that conditional loss of
AR expression in the epithelial compartment, but not in stromal
cells, results in increased luminal epithelial cell proliferation [5,6].
When a physiological level of androgen is not maintained, such as
following androgen ablation, the level of andromedins decreases to
a level where they can neither stimulate proliferation nor block the
activation of apoptosis in the epithelial cells, and thus the prostate
regresses [1].
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dependent signaling mechanisms contribute to the malignant
transformation of epithelial cells [7]. In the AR-independent
pathway, AR protein is not expressed and therefore the AR-
regulated suppression of malignant cell growth is lost. Importantly,
when AR is then ectopically expressed in such AR-independent
prostate cancer cells, androgen-activated AR signaling inhibits cell
growth [8]. In the AR-dependent pathway, AR function is often
converted from a growth suppressor to an oncogene stimulating
prostate cancer cell survival and proliferation [1,9,10]. While
either AR-independent or -dependent pathways are possible, the
majority of prostate cancers acquire oncogenic AR signaling, thus
providing the rationale for why androgen ablation is standard
therapy for metastatic prostate cancer since it inhibits proliferation
and activates apoptosis in these metastatic cancer cells [11].
Moreover, AR signaling remains a central target even for castrate-
resistant metastatic prostate cancers [7]. This is based on the result
of studies showing that, while uncommon in hormonally naı ¨ve
patients, AR gene mutation and amplification, resulting in
elevated AR protein expression, are detected in the majority of
metastatic prostate cancer tissues obtained from patients with
castrate-resistant metastatic disease [12,13]. Consistent with these
clinical observations, AR gene mutation, amplification and protein
over-expression are commonly observed in the majority of prostate
cancer cell lines derived from castrate-resistant hosts [14,15].
These castrate-resistant prostate cancer cell lines do not undergo
apoptosis when androgens are depleted or androgens antagonists
are used; however, they stop proliferating and activate cell death if
the AR protein level is reduced below a critical level both in vitro
[14,16,17] and in vivo [18]. These observations are consistent with
the concept of ‘‘oncogene addiction’’ [19] to AR protein
expression and function, and document that such castrate-resistant
prostate cancer cells remain addicted to AR signaling for their
malignant growth [1,9].
The presence of AR expression, somatic AR mutations or
amplification does not necessarily mean, however, that a prostate
cancer cell is addicted to AR signaling. This statement is based on
the present study, which documents an additional subtype of
human prostate cancer cells. In this subtype, AR has undergone a
dominant-negative, loss-of-function mutation even though AR is
genetically amplified without the patient ever receiving androgen
ablation therapy. Such a dominant-negative loss of AR function in
malignant cells produces a selective growth advantage by
eliminating the normal androgen-dependent AR signaling-
induced growth suppression; however, while necessary, it is
insufficient for these malignant cells acquiring an oncogenic
addiction to AR-signaling.
Methods
Ethics Statement
All animal studies were performed according to animal protocol
MO09M434 approved by the Johns Hopkins Animal Care and
Use Committee specifically for this study.
Cells and Materials
E006AA [20], S006AA [20], LNCaP and PC-3 (obtained from
ATCC, Manassas, VA), and LNCaP C4-2B (obtained from
UroCor, Oklahoma City, OK) cells were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA), and LAPC-4 cells in IMDM
(Invitrogen) plus 1 nM R1881, both containing 10% FBS
(Hyclone, Logan, UT), 16 Pen/Strep, and L-glutamine.
CWR22 xenograft tumor tissue was a kind gift from Thomas
Pretlow (Case Western Reserve University, Cleveland, OH).
Charcoal/dextran stripped FBS (csFBS) was obtained from
Hyclone and used to supplement phenol red-free RPMI (Invitro-
gen) for luciferase and chromatin immunoprecipitation assays.
The synthetic androgen R1881 was purchased from Perkin-Elmer
(Boston, MA). PSA analysis was conducted by the JHMI Clinical
Chemistry Laboratory. Cell growth was measured by a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say (CellTiter Non-Radioactive Cell Proliferation Assay from
Promega Corp. (Madison, WI)). Briefly, cells were plated in a 96-
well format and allowed to adhere overnight. Cells were treated
with vehicle or drug. At specific days, 15 ml of the MTT dye
reagent was added to each well, plates incubated at 37uC for 4 hrs,
100 ml of Stop reagent was added to each well, and plates read by
a Molecular Devices SpectraMAX plus plate reader at 570 and
650 nm. Absorbance readings were then plotted against a
standard curve to determine cell numbers. Results are presented
from day 4. Clonogenic survival was assayed as follows: 500 cells
(parental E006AA, E006AA LV-non-silencing-shRNA, and
E006AA LV-AR-shRNA) were plated per well in 6-well plates,
allowed to adhere and colonize for six days, then simultaneously
fixed and stained in a 0.5% crystal violet/25% methanol solution
and colonies were counted manually.
Karyotype Analyses and Fluorescence in Situ
Hybridization
Cytogenetic analysis was performed using standard methods.
Chromosomal abnormalities were described according to ISCN
guidelines [21]. FISH was performed on the cell lines and on a
normal male control using probes purchased from Vysis (Abbott
Molecular), specific for the AR Gene (Xq12) and X centromere.
The hybridization was done according to manufacturer’s instruc-
tions. For each cell line, 100 interphase nuclei were scored and the
ratio of red (AR) to green (Xcen) signals was calculated. A total of
9–20 metaphases were also analyzed. Images were acquired using
a standard epifluorescence microscope and FISH View software
(Applied Spectral Imaging).
In vivo Tumor Assays
In vivo growth assays were performed as previously described
[22,23]. For subcutaneous injections, one million E006AA cells in
200 ml of 80% Matrigel (BD Biosciences, diluted with cold HBSS)
were injected into the flanks of male Nude or NOG-SCID mice.
For CWR22 xenograft inoculations, 20 mg of tissue was injected
per mouse. Surgical castration was done as previously described
[22,23]. Passage of tumor tissue was conducted by mincing the
tumor tissue, passing it through a sterile tissue strainer, washing it
in PBS, and re-injecting 50 mg of tumor in 200 ml of 80%
Matrigel.
Immunohistological Detection
Immunostaining for AR (N-20; Santa Cruz Biotechnology,
Santa Cruz, CA), PSA (Dako Cytomation, Carpinteria, CA),
DNp63 (LabVison/NeoMarkers, Freemont, CA), Nkx3.1
(UMBC), and CK5 (Babco, Richmond CA) was done on xenograft
sections as previously described [24], with the following modifi-
cations: Tissue sections were deparrafinized, rehydrated and
briefly equilibrated in water. For AR and Nkx3.1 immunohisto-
chemistry, antigen unmasking was performed by boiling slides in
1 mmol/L EDTA (pH 8.0) for 15 min. For p63 staining, slides
were steamed for 20 min in Antigen Unmasking Solution (Vector
Laboratories, Burlingame CA) for 20 minutes. Endogenous
peroxidase activity was quenched by incubation with peroxidase
block for 5 min at room temperature. For AR and Nkx3.1
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bovine serum albumin in Tris-HCl pH 7.5 for 20 min at room
temperature. Slides were incubated with primary antibodies
including a rabbit polyclonal AR antibody (1:25 dilution) for
45 min at room temperature; mouse monoclonal PSA antibody
(1:50 dilution) 45 min at room temperature; mouse monoclonal
p63 antibody (1:50 dilution) for 45 min at room temperature;
rabbit polyclonal Nkx3.1 antibody (1:1000 dilution) for 45 min at
room temperature; and rabbit polyclonal CK5 antibody (1:2500
dilution) for 45 min at room temperature. After primary antibody
application, slides were incubated with poly-HRP conjugated
secondary (EnVision (AR, p63) or PowerVision (PSA, Nkx3.1,
CK5)) at 1:3000 dilution for 30 min at room temperature. Signal
detection was performed using 3,39-diaminobenzidine tetrahy-
drochloride (DAB) as the chromagen for 20 min. Slides were
counterstained with hematoxylin, dehydrated, and mounted.
Lentiviral Infection
Stable wild-type human AR cDNA expression and FACS
sorting for GFP-positive cells was done as previously described
[8,25]. Stable mutant LV-AR S599G was created first by PCR
amplification of E006AA cDNA containing the S599G mutation.
Both the PCR fragment and the wild-type lenti-viral AR plasmid
were restriction digested with Eco81I and Tth111I. Digested PCR
product and LV-AR plasmid were isolated, purified, ligated using
rapid T4 ligase kit (Fermentas), and sequenced to confirm S599G
insertion. Short-hairpin knockdown of AR was conducted using
MISSION
TM lentiviral shRNA transduction particles targeting
either the AR alone or a non-silencing shRNA control (Sigma-
Aldrich, St. Louis, MO). 1610
4 E006AA or LNCaP cells were
plated per well and allowed to adhere for 4 or 24 hrs, respectively.
Cells were transduced at an MOI of 2 (2610
4 particles/well)
without polybrene. Antibiotic selection [1.5 mg/ml puromycin
(Sigma)] was initiated 48 hrs later.
AR Sequencing
RNA was harvested using the Qiagen miRNeasy Mini kit
(Qiagen, Valencia, CA) and contaminating DNA was removed
using the Ambion DNA-free kit (Ambion, Austin, TX). Superscript
reverse transcriptaseIII(Invitrogen,Carlsbad,CA)and 1 mg oftotal
RNA were used to generate cDNAs with Oligo-dT primers.
Genomic DNA was extracted using the Qiagen DNA Mini kit and
incubated with RNase (Roche, Mannheim, Germany) at 37uC for
30 min to remove contaminating RNA. PCR amplification of
cDNAs and genomic DNA was performed using Platinum Pfx DNA
polymerase (Invitrogen) according to the manufacturer’s specifica-
tions with the following overlapping primer sets: (1) 59-AGA-
GAGGTAACTCCCTTTGGCT-39 and 59-ACGCTCTGGAA-
CAGATTCTGG-39 (740bp), (2) 59-TCCCGCAAGTTTC-
CTTCTCT-39 and 59-GATACTGCTTCCTGCTGCTGTT-39
(756bp), (3) 59-TGAGGAACAGCAACCTTCACAG-39 and 59-
ACAGGGTAGACGGCAGTTCAA-39 (704bp), (4) 59-GCCGA-
ATGCAAAGGTTCTCT-39 and 59-TTGACACAAGTGGGAC-
TGGGA-39 (700bp), (5) 59-CAGTTGTATGGACCGTGTGGT-
39 and 59-CTACACCTGGCTCAATGGCT-39 (723bp), (6) 59-
CGGAAGCTGAAGAAACTTGG-39 and 59-AGAAGCGTCTT-
GAGCAGGAT-39 (685bp), (7) 59-ATTCCAGTGGATGGGCT-
GAA-39 and 59-TAGCTCTCTAAACTTCCCGTGG-39 (714bp),
(8) 59-CTTCCCATTGTGGCTCCTAT-39 and 59-ACCTTC-
TCGTCACTATTGGC-39 (361bp); and for genomic DNA
amplification of exon 3 of the AR gene: (9) 59-TGT-
TTGGTGCCATACTCTGTCCAC-39 and 59-GCATCCTCAC-
TCACCTTCTGTTGG-39 (530bp). PCR products were column
purified using the Qiagen QIAquick kit (Qiagen) and were
sequenced at the Johns Hopkins University DNA Analysis Facility
using both forward and reverse primers.
Western Blot Analysis
Whole cell lysates were prepared on a per cell basis in lysis
buffer (20 mM Tris-HCl pH 7.8, 140 nM NaCl, 1 mM EDTA,
0.5% sodium deoxycholate, 0.5% Nonidet P-40) supplemented
with PhosSTOP phosphatase inhibitor tablet and protease
inhibitor tablet (Roche), and 1 mM dithiothreitol. Whole cell
lysates were subjected to SDS-PAGE and transferred to PVDF
membranes. Membranes were blocked in 5% milk (TBS +0.1%
Tween-20) for 1 hr. The rabbit polyclonal AR antibody (SC-816),
and mouse monoclonal CK8 (SC-53266) and mouse monoclonal
CK18 (SC-32722) antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), and the mouse monoclonal ß-
Actin antibody was purchased from Sigma (A5441) and were used
in conjunction with an anti-rabbit-HRP antibody (7074, Cell
Signaling Technology, Danvers, MA) or anti-mouse-HRP
(NA931V, GE Healthcare, UK).
Nuclear and cytoplasmic cell fractions were prepared using the
Nuclear Complex Co-IP kit (Active Motif, Carlsbad, CA)
according to manufacturer’s instructions. In brief, cells were
washed and then scraped in cold PBS supplemented with
phosphatase inhibitors. Cell pellets were resuspended and lysed
in 16 hypotonic solution plus detergent, centrifuged at 6,0006g
for 5 min at 4uC, and cytoplasmic fractions removed. Nuclear
pellets were resuspended in digestion buffer plus enzymatic
shearing cocktail and incubated at 4uC for 90 min. 0.5 M EDTA
was added to stop enzymatic shearing reactions and nuclear lysates
centrifuged for 10 min at 4uC. All fractions were combined with
equal volume 26 SDS-sample buffer and denatured at 95uC for
5 min. Samples were separated on 4–15% PAGE and blotted with
either the anti-AR (N-20; Santa Cruz), the cytoplasmic marker
Vinculin (Sigma), or the nuclear marker HDAC (Santa Cruz
Biotechnologies).
Measuring AR Transcriptional Activity
Cells were plated (per well) in white polystyrene, clear bottom,
sterile 96-well tissue culture plates accordingly: LNCaP C4-2B
(9,000); PC-3 (7,000); E006AA, E006AA LV-AR, E006AA LV-
non-silencing-shRNA, E006AA LV-AR-shRNA (5,000). Cells with
or without androgen (1.0 nM R1881) were plated in six replicates
in RPMI (Invitrogen) supplemented with 10% csFBS (Hyclone)
but without phenol red or pen/strep and allowed to adhere
overnight. Cells were transfected using Fugene 6 (Roche) with
50 ng Probasin-PSA-firefly and 5 ng pRL-TK-renilla (Promega,
Madison, WI) Luciferase reporter constructs per well at a ratio of
3:1 (ml Fugene: mg total DNA) in serum-free media [26]. On day
three, six treatment wells were stimulated with androgen while six
control wells received 0.1% vehicle. On day 4, media was carefully
aspirated and the cells were processed according to the Dual
Luciferase Assay kit instructions (Promega # E1910). Briefly, 30 ml
of passive lysis buffer was added to each well and the plate agitated
on a shaker for 15 min at room temperature. Firefly and renilla
enzymatic activity was measured using a Wallac Jet 1450
Microbeta plate injector. Triple transfected LNCaP C4-2B cells
received 50 ng Probasin-PSA-firefly, 5 ng pRL-TK-renilla, and
50 ng LV-AR-S599G constructs per well at a ratio of 3:1 (ml
Fugene: mg total DNA) in serum-free media.
Chromatin Immunoprecipitation
LNCaP C4-2B and E006AA cells grown in phenol red-free
RPMI, supplemented with 10% csFBS, were harvested via
trypsinization and chromatin prepared according to the Magna-
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7 cells were
resuspended in 10 ml media, fixed by adding 275 ml of 37%
formaldehyde and gently shaken at 22uC for 12 min. After
crosslinking, 1 ml of glycine was added and cells gently shaken for
5 min at 22uC, washed twice in cold PBS, resuspended in 500 ml
cell lysis buffer plus 2.5 ml protease inhibitors (5 mM PIPES pH 8,
85 mM KCl, 0.5% NP-40) and centrifuged for 5 min at 4uC. Cell
pellets were resuspended in 500 ml cell lysis buffer plus 2.5 ml
protease inhibitors, incubated 15 min on ice with brief vortex
every 5 min, and centrifuged at 8006g for 5 min at 4uC. Nuclear
pellets were resuspended in nuclear lysis buffer plus 2.5 ml protease
inhibitors (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1).
Chromatin was sonicated to an average DNA length of 500–1200
bp using Fisher Scientific Sonic Dismembrator Model 100
(4615 sec pulses at setting 3). Five ml was saved for control input
and 50 ml aliquots were diluted in 450 ml dilution buffer (0.01%
SDS, 1.1% Triton, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1,
167 mM NaCl). Four mg of antibody was added to respective
tubes: 4 ml of 1 mg/ml rabbit IgG or 40 ml 100 mg/ml rabbit anti-
AR (SC-816, Santa Cruz) and rotated O/N at 4uC. Immune
complexes were centrifuged 10 min at 10,0006g for 4uC to pellet
any aggregates or non-specific complexes. The supernatant
(desired immune complexes) was harvested and combined with
20 ml protein A Dynabeads (Invitrogen, CA) and gently stirred
2 hrs at 4uC. Tubes were placed in a Millipore magnetic rack and
immune complexes sequentially washed 1 time with low salt buffer
(0.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris-HCl pH 8.1,
150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton, 2 mM
EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl), LiCl buffer,
and TE, with 3 min stirring each wash step. To reverse the
crosslinks, beads were resuspended in 100 ml of Chelex and boiled
10 min at 95uC, centrifuged 1 min at 12,0006ga t4 uC, and
supernatants collected. Beads were resuspended in 120 ml water,
centrifuged again, and supernatants pooled with previous
supernatant. The captured DNA was purified using the Qiagen
PCR purification kit (#28104) according to manufacturer’s
instructions and analyzed by PCR and q-PCR.
PCR Analysis of Immunoprecipitated DNA
Using 5 Prime HotMasterMix (Eppendorf), PCR reactions were
performed as follows: 94uC for 2 min, then 32 cycles 30 sec
denaturation at 94uC, 30 sec of annealing (as indicated below for
each primer pair), and 30 sec of elongation at 65uC, then a 2 min
final elongation at 65uC. PCR products were separated on 2%
Agarose gels and stained with ethidium bromide. Primers for
amplification of DNA fragments are as follows: PSA promoter
ARE (52uC) fwd 59-GCCAAGACATCTATTTCAGGAGC-39,
rev 59-CCCACACCCAGAGCTGTGGAAGG-39; KLK2 pro-
moter (52uC) fwd 59-CTCCAGACTGATCTAGTATG-39, rev
59-TTGGCACCTAGATGCTGACC-39; SP1 site P45
Skp2 pro-
moter (53uC) fwd 59-GATCCACGCTCAGAGACGAC-39, rev
59-TTCGAGATACCCACAACCCC-39; Tcf4 binding element in
c-Myc promoter (55uC) fwd 59-GCTCTCCACTTGCCCCT-
TTTA-39, rev 59-GTTCCCAATTTCTCAGCC-39.
Quantitative PCR Analysis of Immunoprecipitated DNA
Using BioRad IQ SYBER Green Supermix (Hercules, CA),
PCR reactions were performed with the BioRad ICycler as
follows: 95uC for 3 min, then 40 cycles 30 sec denaturation at
95uC, 30 sec of annealing at 55uC, and 45 sec of elongation at
72uC (data were collected during extension), followed by a
110cycle melt curve from 45–100uC to ensure primer efficiency.
Previously designed primers for quantitative amplification of DNA
fragments containing a putative ARE in the PSA gene promoter
and an ARE III in the PSA enhancer region are: ARE fwd 59-
CCTAGATGAAGTCTCCATGAGCTACA-39, rev 59-GGGA-
GGGAGAGCTAGCACTTG-39; ARE III fwd 59-TGGGA-
CAACTTGCAAACCTG-39, rev 59-CCAGAGTAGGTCTGT-
TTTCAATCCA-39 [27]. Percent input calculations were done as
follows: % input =2(CtAR ChIP –C t input)x100. Student’s t-test was
used to determine p-value.
Results
E006AA Cells are Tumorigenic in Intact and Castrated
NOG-SCID Mice
Koochekpour et al. reported the establishment of a new human
prostate cancer cell line, E006AA, which was derived from a
Gleason 6 localized prostate cancer in a hormone-naı ¨ve prostate
cancer patient of African American descent [20]. Matching
normal prostate stromal cells, termed S006AA, were also cultured
from the same radical prostatectomy specimen [20]. The epithelial
origin of the E006AA cells was confirmed by positive expression
for cytokeratins 8 (CK8) and 18 (CK18), whereas the stromal
origin of the S006AA cells was confirmed by the positive
expression of mesenchymal markers desmin and alpha-smooth
muscle actin and the absence of CK8 and CK18 [20]. In the
original studies, E006AA cells were non-tumorigenic when
xenografted into intact male nude mice [20]. Since nude mice
have abnormally high levels of activated natural killer (NK) T-
cells, resulting in an increased host immuno-reactivity towards a
growing tumor [28], this raised the question of whether these
E006AA cells were immortalized but only partially transformed or
whether they are fully malignant but sensitive to NK cell killing.
To resolve this issue, E006AA cell subcutaneous inoculations into
both intact male nude and NOG/SCID/cc
null triple deficient mice
[i.e., NOG-SCID mice deficient in NK, B, and T-cells] were
initiated [29]. Inoculation of E006AA cells into nude mice (n=15)
demonstrated that E006AA cells form palpable tumors, reaching
,100–200 mm
3 by six weeks, in 100% of the mice. After six
weeks, however, all of the E006AA tumors in intact male nude
mice stopped growing and regressed over a second period of 5–10
weeks (Figure 1A). In contrast to the situation in nude mice,
E006AA tumors grew at an accelerated rate in NOG-SCID mice
and did not regress (Figure 1A). Interestingly, although tumori-
genic, no serum PSA could be detected in E006AA tumor-bearing
mice (n=10).
To further confirm that the observed spontaneous regression of
E006AA xenograft tumors in nude hosts, but not in NOG-SCID
mice, stems from immune recognition and elimination by NK
cells, we removed an established and growing E006AA tumor
from a NOG-SCID host and transplanted tissue from this tumor
back into either intact male NOG-SCID (n=5) or nude mice
(n=5). Similar to our previous observations, transplanted E006AA
tumors underwent delayed regression in intact male nude mice
while forming continuously growing tumors in NOG-SCID hosts
(Figure 1B). These combined results document that E006AA cells
are indeed tumorigenic but vulnerable to NK cell killing.
Having demonstrated the tumorigenicity of E006AA cells, we
next evaluated their androgen responsiveness, in vivo,b y
inoculating these cells into both intact (n=10) and castrated
(n=8) male NOG-SCID hosts. Tumors developed equally well in
both hosts and there was no difference in the growth rate or tumor
volume in the castrated vs. intact NOG-SCID animals (Figure 1C).
To ensure castrate levels of circulating androgens, the growth of
the androgen-responsive CWR22 human prostate cancer xeno-
graft in castrated (n=5) vs. intact (n=5) male mice was also
analyzed. Unlike in intact mice, the growth of CWR22 xenograft
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These results document that E006AA cells exhibit castrate-
resistant growth, in vivo, even though they were originally
established from a hormonally naı ¨ve primary prostate cancer.
To characterize the phenotype of these E006AA cells, NOG-
SCID xenograft tumors were removed and processed for
histological and immunohistochemical analysis. Figure 1D illus-
trates that E006AA cells are locally invasive, penetrating skeletal
muscle fibers at the local site of inoculation with the invading cells
exhibiting hallmark features of enlarged and polymorphic cancer
cell nuclei in which AR protein expression is detectable. In
agreement with previous serum analysis, the E006AA xenograft
cells did not stain positive for PSA (Figure 1D), or AR-regulated
Nkx 3.1 proteins (data not shown). Additionally, the cancer cells
lacked expression of the basal cell specific marker, p63, but were
positive for epithelial cell markers cytokeratin 5 (CK5) (Figure 1D),
CK8 and CK18 (Figure 1E), further confirming the epithelial
origin of the E006AA cells [30,31,32].
To rule out an alternate explanation for why E006AA cells were
shown to be tumorigenic in the present study, yet non-tumorigenic
in the original studies, E006AA cells routinely maintained in vitro
were karyotyped directly from cell culture (Figure 2A) and found
to have an identical, abnormal karyotype as originally reported for
the E006AA cell line [20]. Such cells were inoculated into NOG-
SCID hosts and a continuously growing tumor was subsequently
harvested to re-establish in vitro E006AA cultures. Karyotype
analysis of these tumor-derived E006AA cells documented the
same abnormal karyotype, as seen in the in vitro-maintained cell
line (Figure 2B), eliminating the possibility that E006AA cells
became genetically unstable after inoculation into NOG-SCID
mice and developed additional cytogenetic changes that completed
their malignant transformation into a tumorigenic variant.
Amplification, Mutation, and Expression of AR in
Castrate-Resistant E006AA Cells
Fluorescence in Situ Hybridization (FISH) was performed with
probes specific for the AR gene [Xq12] (red signal) and the X
centromere (green signal) (Figure 3A). Interphase analysis
demonstrated that in 91% of cells examined, there were two red
signals associated with each green signal. Since there is a
duplication of the X-chromosome, this means that, on average,
the AR gene is amplified at least four-fold in the E006AA cell line.
Sequencing of overlapping primer PCR amplifications of
E006AA AR cDNA revealed a single point mutation in the
dimerization interface of the AR DNA binding domain (DBD)
(Figure 3B). Sequencing also documented an overall 2,766 bp AR
coding sequence consisting of a 27 aa polyglutamine tract (26
CAG repeats followed by one CAA), an 8 aa polyproline tract, and
a 20 aa polyglycine tract. Koochekpour et al. originally reported
26 CAG repeats, which is in agreement with our analysis [20].
The point mutation is a missense mutation in the third exon
consisting of a single nucleotide change from adenine to guanine at
the 1795
th position (AGC to GGC). This single base change results
in an amino acid substitution from serine to glycine at position 599
(S599G, Figure 3B). The S599G amino acid mutation corresponds
with Ser597 in the reference AR protein sequence (NM_000044),
due to an overall increase of two amino acids from the altered
polyglutamine and polyglycine tracts. The significance of the
S599G mutation pertains to its precise location at the AR
dimerization interface and the documented role of this serine
residue in supporting receptor dimerization when AR is bound to
DNA [33,34]. In other words, a serine-to-glycine change at this
position, producing what is referred to as a ‘‘glycine hole’’, disrupts
the cross-dimer serine-serine hydrogen bond, which normally is
crucial in promoting stability of the AR homodimer at the DNA
interface.
To validate this single nucleotide change, each E006AA cDNA
PCR product, generated from multiple cell passages, was
sequenced using both sense and anti-sense primers. Additionally,
genomic DNA was obtained from E006AA as well as from the
patient-matched S006AA cells; PCR amplification using an
intronic forward primer and an exonic reverse primer, designed
to amplify only the mutation-containing region in exon 3, verified
that E006AA cancer cells harbor the S599G mutation while the
matching stromal S006AA cells do not. All sequencing reactions
demonstrated an unambiguous signal at the mutation site,
indicating that amplified copies of the AR gene within E006AA
cells all harbor the same mutation. These data document that the
AR gene mutation in E006AA was a somatic mutation that
likely occurred prior to gene amplification and X-chromosome
duplication.
Quantitative PCR analysis of AR mRNA in E006AA compared
to LNCaP cells found that E006AA cells express approximately
23-fold lower levels of AR transcript than LNCaP cells (Figure 3C),
but when compared to patient-matched S006AA normal prostate
stromal cells, E006AA cells express a .10-fold higher level of AR
protein (Figure 3D). However, it is important to note that when
compared to other commonly used AR-expressing prostate cancer
cell lines (i.e., LNCaP, LNCaP C4-2B, LAPC4), the levels of AR
protein expressed by E006AA cells is approximately five- to ten-
fold lower (Figure 3D) [13].
Effect of Wild-Type AR Expression and shRNA AR
Knockdown on E006AA Growth
Paradoxically, while AR is mutated and amplified in E006AA
cells, the in vitro growth of these cells, as determined by a cell
growth and viability MTT assay normalized for cell counts, is not
affected by the addition of an increasing dose of synthetic
androgen (e.g., 1.0 to 100 nM R1881), or anti-androgen (e.g.,
10 mM Casodex) (Figure 4A). Also, E006AA cells fail to produce
detectable levels of secreted PSA protein (,0.1 ng/ml in media),
which agrees with our in vivo serum and immunohistochemical
analysis (Figure 1D) and, as reported originally by Koochekpour
et al., E006AA cells do not express PSMA or PSAP [20]. One
possibility is that this lack of ligand-dependent androgenic
response could be explained by reduced stability of AR
dimerization at the DNA interface due to the S599G mutation.
To begin resolving whether the lack of AR signaling is due to
the mutant AR, wild-type AR (wt-AR) was introduced into
E006AA cells via lentiviral transduction, to co-express ectopic wt-
AR, and cells isolated via fluorescence activated cell sorting
(FACS) for GFP-positive cells [8]. Such E006AA LV-AR sorted
Figure 1. E006AA cells are tumorigenic and immunogenic in nude mice, and do not require a physiologic level of testosterone for
growth. (A) Inoculation of E006AA cells into male nude mice compared to male NOG-SCID mice. (B) Transfer of tumor tissue derived from an
established E006AA xenograft tumor from a male NOG-SCID mouse to intact male Nude and NOG-SCID mice. (C) The growth of E006AA and CWR22
human prostate cancer xenograft tumors in castrated vs. intact male mice at eight weeks. (D) Histological analysis (H&E) and immunostaining of
E006AA xenograft tissue sections for AR, PSA, p63, and CK5 (images taken at 206and 406). (E) Western blot analysis of CK8 and CK18 expression in
LNCaP, PC-3, E006AA and S006AA cells. ß-Actin served as a loading control.
doi:10.1371/journal.pone.0011475.g001
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11475Figure 2. Karyotype Analysis of E006AA cells. (A) Karyotype analysis of E006AA cells prior to injection and in vivo tumor growth. (B) Analysis of
E006AA cells derived from a NOG-SCID tumor-bearing mouse, documenting no significant karyotypic alterations during tumor growth.
doi:10.1371/journal.pone.0011475.g002
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PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11475cells expressed ,3:1 ratio of wt-AR to mutant AR protein based
upon comparison to parental cells expressing only mutant AR
protein (Figure 3D). Even with such over expression of wt-AR
protein, growth of E006AA LV-AR cells was not affected by the
synthetic androgen R1881 or inhibited by the anti-androgen
Casodex (Figure 4A). Interestingly, expression of wt-AR also failed
to induce any detectable secreted PSA protein (,0.1 ng/ml in
media) even in the presence of added R1881.
These results raise the issue of whether AR signaling is needed
at all for the growth of E006AA cells. To address this, AR protein
expression was suppressed using infection of anti-AR shRNA
lentiviral particles. Western blotting confirmed a stable .95%
knockdown of AR protein in these E006AA LV-AR-shRNA
transduced cells (Figure 3D). Such AR protein knockdown,
however, had no effect on either cell growth (Figure 4B) or
clonogenic survival (Figure 4C). To verify the shRNA specificity
for AR knockdown, transduction of LNCaP cells with the same
AR shRNA lentiviral particles dramatically inhibited LNCaP cell
growth and clonogenic survival (data not shown), as has been
previously reported [35]. In conjunction with our in vivo castration
studies, these data demonstrate that the growth of E006AA cells is
not dependent on AR protein expression and function.
Ligand-Bound AR Translocates to the Nucleus, Binds
DNA, but is not Transcriptionally Active
The inability of both wt-AR expression and targeted knock-
down of the endogenous mutant AR to affect the growth of
E006AA cells implies that the AR signaling machinery is deficient
in E006AA cells. This could involve, among many possible
mechanisms, impaired AR nuclear translocation or a loss-of-
function due to the S599G mutation. To test this, the nuclear
translocation and transcriptional activity of both the mutant and
exogenously expressed wt-AR were analyzed. It has been well
documented that, in the absence of ligand, AR is predominantly
localized in the cytoplasm; however, upon binding ligand they
localize to the nucleus where they bind DNA and activate target
genes [1,36,37,38]. E006AA cells, which were either depleted of or
treated with androgen, were lysed and fractioned into nuclear and
cytoplasmic fractions (Figure 5A). As controls, the castration-
resistant and AR-positive prostate cancer cell line LNCaP C4-2B
and the AR-negative prostate cancer cell line PC-3 were used. In
agreement with previous studies [1,37,38], the majority of AR
protein was detected in cytoplasmic fractions of both LNCaP C4-
2B and E006AA cells grown in reduced androgen conditions
(Figure 5A). Importantly, AR in LNCaP C4-2B cells as well as
both the endogenous mutant AR and the lentiviral expressed wt-
AR in E006AA cells translocates to the nucleus upon the addition
of ligand (Figure 5A), documenting that E006AA cells possess the
necessary cellular components to shuttle the AR into the nucleus
upon ligand binding.
Knowing that endogenous, mutant AR in E006AA cells
translocates to the nucleus upon stimulation with androgen, the
next step was to evaluate whether the S599G mutant AR in
E006AA cells had the capacity to bind DNA. Using an anti-AR
antibody, chromatin was immunoprecipitated from E006AA and
LNCaP C4-2B cells grown in reduced serum conditions (csFBS +
phenol red-free RPMI) in the presence or absence of androgen.
The captured DNA was subjected to semi-quantitative PCR
amplification using primers designed to amplify putative androgen
response elements (ARE) located in the PSA promoter. Positive
amplification is detected in AR-immunoprecipitated chromatin
from both E006AA and C4-2B cells, demonstrating that the
endogenous, mutant AR expressed in E006AA cells binds DNA,
regardless of the presence of ligand (Figure 5B). To test a wider
array of AR-binding sites, PCR analysis was performed using
primers targeting the AR-regulated Sp1(A) site in the human
p45
Skp2 promoter [39], the AR binding site in the human KLK2
promoter [40], and the AR-associated Tcf4 binding element in the
c-Myc promoter [41], all of which demonstrated unambiguous
amplification of AR-immunoprecipitated chromatin (data not
shown). Additionally, quantitative PCR, using primers designed to
amplify a similar ARE-containing region in the PSA promoter
[27] and a putative androgen response element III (ARE III)
located in the PSA enhancer [27], was performed to evaluate the
effect of androgenic stimulation on the DNA binding ability of
mutant, endogenous AR in E006AA cells. As seen using semi-
quantitative PCR, AR from both LNCaP C4-2B and E006AA
cells was detected at the PSA promoter (Figure 5Ci, Ciii).
Surprisingly, we observed positive amplification at the PSA
enhancer region from both LNCaP C4-2B and E006AA
immunoprecipitated chromatin samples, regardless of ligand
stimulation (Figure 5Cii, Civ). However, this experiment revealed
that, although mutant AR in E006AA cells can be found at the
promoter ARE and enhancer ARE III sites, androgenic
stimulation failed to increase S599G AR presence at either site,
in contrast to what was observed in the LNCaP C4-2B cells
(Figure 5C).
To test whether endogenous AR in E006AA cells possesses the
capacity for AR-mediated gene transcription, transient transfec-
tion assays were performed using a Probasin-PSA-Firefly Lucifer-
ase vector, which is optimized for measuring AR transcriptional
activity [26]. Using steroid-depleted, serum-containing media,
Luciferase activity was tested in the absence and presence of
exogenous androgen. Endogenous, mutant AR in E006AA cells
failed to drive Luciferase expression from the AR-mediated
promoter construct (Figure 5D). In agreement with the previous
finding that E006AA LV-AR cells did not secrete detectable PSA,
introduction of wt-AR also failed to induce Luciferase expression
(Figure 5D); previous data have documented that such wt-AR
expression is capable of driving AR-mediated gene transcription in
appropriate cells [8].
The earlier demonstration that S599G mutant AR in E006AA
cells translocates to the nucleus upon androgenic stimulation,
where it effectively binds ARE-containing DNA but does not
stimulate transcription of AR target genes, raises the issue of
whether the S599G mutation results in a loss-of-function. To
evaluate this possibility, the S599G mutant AR was cloned and
placed in a Lentiviral vector to create a LV-AR-S599G construct.
We then assessed Luciferase activity in the positive control LNCaP
Figure 3. Somatic AR mutation and amplification in E006AA cells. (A) Cytogenetic analysis of AR status in normal male control and E006AA
cells as determined by Fluorescence in Situ Hybridization (FISH) using probes specific for the AR Gene (Xq12, red colored) and the X centromere
(green colored). (B) Sequencing results of overlapping primer PCR amplification of E006AA mRNA and cDNA identified a missense mutation
(Ser599Gly), which corresponds to the ‘‘X’’ position of the conserved AXRND motif in the DBD D-box (as denoted by black arrowhead at position 597
of the reference human AR NM_000044), as found in human AR, GR, PR, and MR. (C) Quantitative PCR analysis of AR mRNA transcript levels in LNCaP
compared to E006AA cells. (D) Western blot analysis of AR protein expression in E006AA cells infected with lentiviral non-silencing shRNA, wild-type
AR (Lenti-AR), or anti-AR shRNA (AR shRNA) constructs compared to parental E006AA, LNCaP, PC-3 and S006AA stromal cells. Protein lysates were
loaded on a per cell basis as follows: LNCaP (20,000), all others (200,000) cells per lane.
doi:10.1371/journal.pone.0011475.g003
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PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11475C4-2B cells transiently co-transfected with the LV-AR-S599G and
Probasin-PSA-Firefly Luciferase vectors. In LNCaP C4-2B cells
transiently expressing S599G AR, Luciferase activity was reduced
63%, in multiple experiments, compared to parental LNCaP C4-
2B cells (Figure 5E). These combined results document that the
S599G mutation is a dominant-negative loss-of-function mutation
that disrupts normal AR signaling.
Discussion
Prostate cancer cells can be subdivided based upon AR protein
status and response to castration. In one subtype, AR protein is not
expressed (e.g., PC-3 and DU-145) and thus cell survival and
proliferation is completely independent of AR signaling. These AR
negative cells are thus castration resistant. In another subtype of
prostate cancer cells (e.g., PC-82 and CWR22), AR is expressed
and has acquired a gain-of-function such that it no longer inhibits
but now stimulates proliferation when activated by physiological
levels of androgen [13]. Thus, this subtype of AR-expressing
prostate cancer cells remains castrate-sensitive. In a second
subtype of AR-expressing prostate cancer cells derived from
castrated patients (e.g., LNCaP, LAPC-4, MDA-PC-2B, VCAP,
etc), the cells have developed castration resistance mechanisms
(i.e., mutation, gene amplification, protein over-expression) to
activate AR signaling for their continued growth even in the
presence of castrate levels of androgen [7].
E006AA cells represent a third new subtype of AR-expressing
prostate cancer cells, which exhibit castrate-resistant growth
characteristics even though these cells were derived from a
hormonally naı ¨ve patient. E006AA cells possess many of the same
molecular characteristic changes commonly observed in prostate
cancer metastases and cell lines derived from patients who were
androgen ablated. These include AR gene amplification and
mutation. The significance of the S599G mutation is its precise
location within the DBD, and more specifically in the dimerization
interface region known as the D box [34]. Originally characterized
from the co-crystal structure of the glucocorticoid receptor (GR)
DBD bound to an inverted-repeat 4 DNA element (GR-DBD-
IR4), the D-box loop structure contains a conserved AXRND
motif within the second zinc-finger of the DBD [42]. The D-box
sequence found in the GR, progesterone receptor (PR), and
mineralocorticoid receptor (MR) contains an AGRND motif
whereas AR contains an ASRND motif (Figure 3B). A change
from serine to glycine at the ‘‘X’’ position of the mutated AR in
E006AA cells destroys the crucial serine-serine hydrogen bond,
which is thought to increase the stability of the AR homodimer at
the DNA interface, resulting in what is referred to as a ‘‘glycine
hole’’ (Figure 3B) [33]. If such a substitution sufficiently impairs
the AR:DNA interaction [33], this loss-of-function mutation might
explain the apparent lack of AR responsiveness observed in
E006AA cells. The results presented here, which demonstrate that
endogenous mutant AR in E006AA cells interacts with ARE-
containing DNA, that E006AA AR fails to drive an AR-regulated
luciferase construct, and that the S599G mutant AR, when cloned
into an AR-responsive cell line that we know possesses all the
necessary PSA transcription co-factors, profoundly inhibits
endogenous AR transcriptional function, implicate the S599G
mutation as a dominant-negative mechanism sufficient in shutting
down the AR signaling axis in E006AA cells. Interestingly, this
specific S599G substitution has been identified in male patients
with androgen insensitivity syndrome (AIS) [43,44] and is
catalogued in the McGill University’s AR gene mutations database
for AIS [http://androgendb.mcgill.ca], but has not been previ-
ously linked with prostate cancer. This mutation, however, does
not disrupt normal androgen binding kinetics [44], which agrees
with our data showing that androgens can drive endogenous,
mutant AR into the nucleus.
The defining characteristic of E006AA cells is the complete
absence of AR growth-regulatory function, even though these cells
express AR protein. This raises the issue of why such molecular
changes in AR (i.e., gene amplification and a loss-of-function
mutation) would have a selective advantage. One explanation is
that while these changes prevent AR signaling from promoting
either survival or proliferation of malignant prostate cells, the lack
of AR signaling eliminates the growth suppression normally
induced by AR signaling in non-transformed prostate epithelial
cells in a host with normal physiological levels of androgen. This is
consistent with the loss of AR-mediated growth suppression
providing a selective growth advantage, even without the
simultaneous acquisition of a gain-of-function ability of AR
signaling to stimulate survival and proliferation. This suggests
that the biochemical mechanism for loss of AR signaling-induced
growth suppression is not identical, and not always coupled, to that
associated with the gain of AR signaling-induced growth
stimulation in prostate cancer cells. The inability to express AR
regulated genes, such as PSA, Nkx3.1, and KLK2, could also be
due to alterations in the AR transcriptional machinery in E006AA
cells, in addition to possible epigenetic changes that have altered
the chromatin configuration found in E006AA cells. These
possibilities raise important questions for future studies and
defining these distinguishable mechanisms is a focus of our
ongoing experiments, for which E006AA cells are an important
reagent.
Regardless of the mechanism, the realization that loss of growth
suppression and gain of survival and proliferation stimulation by
AR signaling are distinct processes has significant clinical
implications. For example, as many as 50% of patients with
castrate-resistant metastatic prostate cancer have circulating
cancer cells that have substantial amplification of the AR locus,
which has been interpreted to predict that, in such patients,
androgen signaling continues to play an important growth
stimulatory role [45]. The present data show, however, that this
is not always true, since expression of mutated and amplified AR
within E006AA cells serves no stimulatory function for either
survival or proliferation. These results have a series of clinical
implications: 1) AR gene mutation, amplification, or altered
expression do not occur only following androgen ablation, 2) such
molecular changes do not always result in AR signaling being
required for either the survival or proliferation of prostate cancer
cells, and 3) detection of such AR changes cannot be used
absolutely to predict clinical response to AR axis-targeted therapy.
An important clinical corollary to these conclusions is that there
exists a subtype of prostate cancers for which a more aggressive
hormone therapy regimen or anti-AR therapy will elicit no clinical
benefit, even though they possess AR mutation or amplification.
Figure 4. In vitro growth response to modulation of AR expression in E006AA cells. (A) Cell growth analyses of E006AA cells transduced
with or without Lentiviral wild-type AR, which were then treated with 10 mM Casodex or an increasing dose of R1881 (1.0 nM to 100 nM). Cell growth
is graphed relative to the respective untreated control cells. (B) Comparison of vector only Lentiviral-non-silencing, Lenti-AR, and Lenti-AR-shRNA
transduced E006AA cell growth relative to control cells. (C) Colony forming assay comparing parental control cells to non-silencing, and two different
anti-AR Lenti-shRNA sequences (3715 and 3718).
doi:10.1371/journal.pone.0011475.g004
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PLoS ONE | www.plosone.org 11 July 2010 | Volume 5 | Issue 7 | e11475Figure 5. AR in E006AA cells undergoes nuclear translocation, binds DNA but is not transcriptionally activity due to the S599G loss-
of-function mutation. (A) Western blot analysis of nuclear and cytoplasmic AR expression in LNCaP C4-2B, PC-3, and E006AA cells, treated with or
without androgen. E006AA fractions were blotted for Vinculin and HDAC to confirm suitable cytoplasmic and nuclear separation, respectively. (B) PCR
Loss of AR Growth Function
PLoS ONE | www.plosone.org 12 July 2010 | Volume 5 | Issue 7 | e11475Acknowledgments
We wish to thank Constance Griffin, MD, Raluca Yonescu, MD, and
Laura Morsberger of the Cytogenetics Core Facility, Johns Hopkins
Cancer Center for the Cytogenetics and FISH analyses, Lee Blosser and
Ada Tam of the Johns Hopkins Flow Cytometry Core for the FACS
sorting, and Dr. Angelo De Marzo and Jessica Hicks of the Johns Hopkins
Cancer Center Histology Core for the AR, PSA, p63, Nkx 3.1, and CK5
immunostaining. An early passage (P3) of the tumorigenic E006AA cell line
is available through ATCC. These early passage tumorigenic E006AA cells
have an approximate 70% take rate in vivo when injected in matrigel, and,
on average, take roughly 78 days to form 1cc tumors in NOG mice.
Author Contributions
Conceived and designed the experiments: JMD DJVG JTI. Performed the
experiments: JMD DJVG LA GN SLD. Analyzed the data: JMD DJVG
JTI. Contributed reagents/materials/analysis tools: SK JTI. Wrote the
paper: JMD DJVG.
References
1. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT (2003) Prostate-specific
antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or
prostate cancer xenografts in vivo. Prostate 56: 45–53.
2. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, et al. (2002)
Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ
13: 1–11.
3. Ling MT, Chan KW, Choo CK (2001) Androgen induces differentiation of a
human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line.
J Endocrinol 170: 287–296.
4. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004)
Androgen-induced differentiation and tumorigenicity of human prostate
epithelial cells. Cancer Res 64: 8867–8875.
5. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, et al. (2007) Increased
prostate cell proliferation and loss of cell differentiation in mice lacking prostate
epithelial androgen receptor. Proc Natl Acad Sci U S A 104: 12679–12684.
6. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, et al. (2007)
Disruption of prostate epithelial androgen receptor impedes prostate lobe-
specific growth and function. Endocrinology 148: 2264–2272.
7. Isaacs JT, Isaacs WB (2004) Androgen receptor outwits prostate cancer drugs.
Nat Med 10: 26–27.
8. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, et al. (2006) PC3, but
not DU145, human prostate cancer cells retain the coregulators required for
tumor suppressor ability of androgen receptor. Prostate 66: 1329–1338.
9. Isaacs JT (2000) Apoptosis: translating theory to therapy for prostate cancer.
J Natl Cancer Inst 92: 1367–1369.
10. Vander Griend DJ, Litvinov IV, Isaacs JT (2007) Stabilizing androgen receptor
in mitosis inhibits prostate cancer proliferation. Cell Cycle 6: 647–651.
11. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev
Cancer 2: 389–396.
12. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, et al. (2004) Androgen-
independent prostate cancer is a heterogeneous group of diseases: lessons from a
rapid autopsy program. Cancer Res 64: 9209–9216.
13. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al.
(2003) Molecular characterization of human prostate carcinoma cell lines.
Prostate 57: 205–225.
14. Dehm SM, Tindall DJ (2007) Androgen receptor structural and functional
elements: role and regulation in prostate cancer. Mol Endocrinol 21:
2855–2863.
15. Liu W, Xie CC, Zhu Y, Li T, Sun J, et al. (2008) Homozygous deletions and
recurrent amplifications implicate new genes involved in prostate cancer.
Neoplasia 10: 897–907.
16. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of
androgen receptor function inhibits proliferation of androgen-refractory prostate
cancer cells. Cancer Res 62: 1008–1013.
17. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK (2005) Androgen receptor
signaling is required for androgen-sensitive human prostate cancer cell
proliferation and survival. Cancer Cell Int 5: 8.
18. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo
knockdown of the androgen receptor results in growth inhibition and regression
of well-established, castration-resistant prostate tumors. Clin Cancer Res 15:
39–47.
19. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68: 3077–3080;
discussion 3080.
20. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, et al. (2004)
Establishment and characterization of a primary androgen-responsive African-
American prostate cancer cell line, E006AA. Prostate 60: 141–152.
21. International Standing Committee on Human Cytogenetic Nomenclature,
Shaffer LG, Tommerup N (2005) ISCN 2005: an international system for
human cytogenetic nomenclature (2005): recommendations of the International
Standing Committee on Human Cytogenetic Nomenclature. Basel; Farmington,
CT, Karger 130 p.
22. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, et al. (2003)
Dissociation between androgen responsiveness for malignant growth vs.
expression of prostate specific differentiation markers PSA, hK2, and PSMA
in human prostate cancer models. Prostate 54: 249–257.
23. Gao J, Arnold JT, Isaacs JT (2001) Conversion from a paracrine to an autocrine
mechanism of androgen-stimulated growth during malignant transformation of
prostatic epithelial cells. Cancer Res 61: 5038–5044.
24. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, et al. (2010) Loss of
Nkx3.1 expression in bacterial prostatitis: a potential link between inflammation
and neoplasia. Am J Pathol 176: 2259–2268.
25. Litvinov IV, Antony L, Isaacs JT (2004) Molecular characterization of an
improved vector for evaluation of the tumor suppressor versus oncogene abilities
of the androgen receptor. Prostate 61: 299–304.
26. van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, et al.
(2001) A novel method for the determination of basal gene expression of tissue-
specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther
8: 927–935.
27. Wang Q, Carroll JS, Brown M (2005) Spatial and temporal recruitment of
androgen receptor and its coactivators involves chromosomal looping and
polymerase tracking. Mol Cell 19: 631–642.
28. Hanna N (1980) Expression of metastatic potential of tumor cells in young nude
mice is correlated with low levels of natural killer cell-mediated cytotoxicity.
Int J Cancer 26: 675–680.
29. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/
SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraft-
ment of human cells. Blood 100: 3175–3182.
30. Hudson DL, Guy AT, Fry P, O’Hare MJ, Watt FM, et al. (2001) Epithelial cell
differentiation pathways in the human prostate: identification of intermediate
phenotypes by keratin expression. J Histochem Cytochem 49: 271–278.
31. Litvinov IV, De Marzo AM, Isaacs JT (2003) Is the Achilles’ heel for prostate
cancer therapy a gain of function in androgen receptor signaling? J Clin
Endocrinol Metab 88: 2972–2982.
32. Long RM, Morrissey C, Fitzpatrick JM, Watson RW (2005) Prostate epithelial
cell differentiation and its relevance to the understanding of prostate cancer
therapies. Clin Sci (Lond) 108: 1–11.
33. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT (2004) Structural
basis of androgen receptor binding to selective androgen response elements. Proc
Natl Acad Sci U S A 101: 4758–4763.
34. Verrijdt G, Haelens A, Claessens F (2003) Selective DNA recognition by the
androgen receptor as a mechanism for hormone-specific regulation of gene
expression. Mol Genet Metab 78: 175–185.
35. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, et al. (2007) A promoting role of
androgen receptor in androgen-sensitive and -insensitive prostate cancer cells.
Nucleic Acids Res 35: 2767–2776.
36. Jensen EV, Suzuki T, Kawashima T, Stumpf WE, Jungblut PW, et al. (1968) A
two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl
Acad Sci U S A 59: 632–638.
37. Simental JA, Sar M, Lane MV, French FS, Wilson EM (1991) Transcriptional
activation and nuclear targeting signals of the human androgen receptor. J Biol
Chem 266: 510–518.
amplification of a putative ARE in the PSA promoter region from anti-AR immunoprecipitated chromatin from LNCaP C4-2B and E006AA cells, treated
with or without androgen. Chromatin immunoprecipitated with an IgG isotype served as a negative control. (C) Quantitative PCR analysis of anti-AR
antibody immunoprecipitated chromatin from LNCaP C4-2B and E006AA cells, treated with or without androgen: (Ci) PSA promoter ARE amplification
in C4-2B cells; (Cii) PSA enhancer ARE III amplification in C4-2B cells; (Ciii) PSA promoter ARE amplification in E006AA cells; (Civ) PSA enhancer ARE III
amplification in E006AA cells. The results are presented as percentage of input. (*, p-value ,0.05, Student’s T-test). (D) Analysis of AR transcriptional
activity in E006AA cells compared to LNCaP C4-2B, PC-3, E006AA Lenti-AR, E006AA Lenti-non-silencing-shRNA, E006AA Lenti-AR-shRNA cells, treated
with or without androgen. (E) Introduction of mutant S599G AR into androgen-responsive, PSA producing LNCaP C4-2B cells, and its effect on AR-
driven PSA-Luciferase activity in C4-2B cells, with or without androgen (*, p-value ,0.05, Student’s T-test). All experiments in this section were
performed with cells grown in 10% csFBS supplemented media, +/224 hr stimulation with 1.0 nM R1881.
doi:10.1371/journal.pone.0011475.g005
Loss of AR Growth Function
PLoS ONE | www.plosone.org 13 July 2010 | Volume 5 | Issue 7 | e1147538. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, et al. (2000) Dynamics
of intracellular movement and nucleocytoplasmic recycling of the ligand-
activated androgen receptor in living cells. Mol Endocrinol 14: 1162–1174.
39. Huang YC, Hung WC (2006) 1,25-dihydroxyvitamin D3 transcriptionally
represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells.
J Cell Physiol 209: 363–369.
40. Kang Z, Pirskanen A, Janne OA, Palvimo JJ (2002) Involvement of proteasome
in the dynamic assembly of the androgen receptor transcription complex. J Biol
Chem 277: 48366–48371.
41. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, et al. (2003) A direct
beta-catenin-independent interaction between androgen receptor and T cell
factor 4. J Biol Chem 278: 30828–30834.
42. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, et al. (1991)
Crystallographic analysis of the interaction of the glucocorticoid receptor with
DNA. Nature 352: 497–505.
43. Sultan C, Paris F, Terouanne B, Balaguer P, Georget V, et al. (2001) Disorders
linked to insufficient androgen action in male children. Hum Reprod Update 7:
314–322.
44. Zoppi S, Marcelli M, Deslypere JP, Griffin JE, Wilson JD, et al. (1992) Amino
acid substitutions in the DNA-binding domain of the human androgen receptor
are a frequent cause of receptor-binding positive androgen resistance. Mol
Endocrinol 6: 409–415.
45. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, et al. (2009) Fluorescence in
situ hybridization analysis of circulating tumor cells in metastatic prostate
cancer. Clin Cancer Res 15: 2091–2097.
Loss of AR Growth Function
PLoS ONE | www.plosone.org 14 July 2010 | Volume 5 | Issue 7 | e11475